Paricalcitol.

Paricalcitol activates the vitamin D receptor and raises expression of the intestinal calcium transport machinery. Adding a large calcium load pushes serum calcium in the same direction, so the two are additive and normally monitored together.

Calcium carbonate contributes both an absorbable calcium load and gut phosphate binding, while paricalcitol independently raises absorption of both minerals. The calcium arms of the two add together.

Vitamin D receptor activation increases intestinal phosphate transport alongside calcium. A supplemental phosphate load compounds the same shift in serum phosphate.

Cholecalciferol is converted to calcitriol, which binds the same vitamin D receptor paricalcitol occupies. Running both means two ligands acting at one receptor, so the calcium and phosphate effects add.

Cholecalciferol raises circulating 25-hydroxyvitamin D and downstream calcitriol, a full agonist at the receptor paricalcitol already activates. The signalling is additive rather than complementary.

Calcifediol is one hydroxylation away from calcitriol, the natural ligand of the receptor paricalcitol binds. Supplying it increases native agonist alongside the analogue.

Ergocalciferol is metabolised to 1,25-dihydroxyvitamin D2, which activates the same nuclear receptor. Its calcium and phosphate effects sit on top of the analogue's.

Vitamin D receptor activation raises expression of osteocalcin and matrix Gla protein, and both stay inactive until vitamin K carboxylates their glutamate residues. Menaquinone status determines whether those calcium handling proteins can function.

The hydroxylases that build and clear vitamin D metabolites are magnesium-dependent, and magnesium also participates in parathyroid hormone secretion. Magnesium status shapes the background the analogue acts against.

Vitamin D receptor signalling requires dimerisation with the retinoid X receptor, whose natural ligand is 9-cis retinoic acid, a vitamin A metabolite. The complex binds vitamin D response elements in target gene promoters. Retinoid status is therefore part of the machinery any vitamin D receptor activator, including paricalcitol, works through.

Vitamin D receptor signalling raises transcription of osteocalcin and matrix Gla protein, both of which need vitamin K-dependent gamma-carboxylation of glutamate residues before they can bind calcium. Without adequate vitamin K the induced protein is made but stays undercarboxylated. The relationship is sequential rather than additive.

Paricalcitol appears alongside glutathione and malondialdehyde measurements in rodent models, where those markers track oxidative state rather than any clinical result. There is no human study of the two given together. This is a co-studied laboratory pairing and nothing stronger.